# Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

> **NCT00985517** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 57 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **BIOLOGICAL:** CERE-120: Adeno-Associated Virus Delivery of Neurturin
- **PROCEDURE:** Sham Surgery

## Key facts

- **NCT ID:** NCT00985517
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-29
- **Primary completion:** 2014-11-09
- **Final completion:** 2017-11-16
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985517, "Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00985517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*